JP2007525491A5 - - Google Patents

Download PDF

Info

Publication number
JP2007525491A5
JP2007525491A5 JP2006549895A JP2006549895A JP2007525491A5 JP 2007525491 A5 JP2007525491 A5 JP 2007525491A5 JP 2006549895 A JP2006549895 A JP 2006549895A JP 2006549895 A JP2006549895 A JP 2006549895A JP 2007525491 A5 JP2007525491 A5 JP 2007525491A5
Authority
JP
Japan
Prior art keywords
gpr49
secretase
gamma
beta
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006549895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/013539 external-priority patent/WO2005074980A1/en
Publication of JP2007525491A publication Critical patent/JP2007525491A/ja
Publication of JP2007525491A5 publication Critical patent/JP2007525491A5/ja
Withdrawn legal-status Critical Current

Links

JP2006549895A 2004-01-29 2004-11-29 Ｇｐｒ４９の使用による、神経変性疾患の治療 Withdrawn JP2007525491A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04001895 2004-01-29
EP04001894 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
PCT/EP2004/013539 WO2005074980A1 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases by the use of gpr49

Publications (2)

Publication Number Publication Date
JP2007525491A JP2007525491A (ja) 2007-09-06
JP2007525491A5 true JP2007525491A5 (https=) 2007-12-13

Family

ID=38556372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549895A Withdrawn JP2007525491A (ja) 2004-01-29 2004-11-29 Ｇｐｒ４９の使用による、神経変性疾患の治療

Country Status (11)

Country Link
US (1) US20080025969A1 (https=)
EP (1) EP1713501B1 (https=)
JP (1) JP2007525491A (https=)
AT (1) ATE383870T1 (https=)
AU (1) AU2004315111B2 (https=)
CA (1) CA2554353A1 (https=)
DE (1) DE602004011400T2 (https=)
DK (1) DK1713501T3 (https=)
ES (1) ES2300852T3 (https=)
PT (1) PT1713501E (https=)
WO (2) WO2005074980A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1962584A2 (en) * 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2022848A1 (en) * 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2882826A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9908863B2 (en) 2013-01-10 2018-03-06 Merck Patent Gmbh Piperidinylcarbazoles
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
ES2902143T3 (es) 2014-07-04 2022-03-25 Merck Patent Gmbh Derivados de azepanilo y composiciones farmacéuticas que los comprenden con actividad antiparasitaria

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1146898A1 (en) * 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
DE19941039A1 (de) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-Sekretase in vitro Testsystem
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
JP4344519B2 (ja) * 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
EP1519950A2 (en) * 2002-06-26 2005-04-06 Cellzome Ag Components of the presenilin-complex
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1

Similar Documents

Publication Publication Date Title
JP2007525491A5 (https=)
US12205696B2 (en) Drug device configured for wireless communication
Silletti et al. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
JP2009526754A5 (https=)
Tallant et al. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
CN1321633C (zh) 用no对指甲感染的治疗
Graziani et al. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
JP2006525796A5 (https=)
BRPI0412054A (pt) preparação farmacêutica transdérmica
De Minicis et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
Wang et al. Target identification of kinase inhibitor alisertib (MLN8237) by using DNA‐programmed affinity labeling
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
JP2016516074A5 (https=)
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
Hadaschik et al. Intravesically administered antisense oligonucleotides targeting heat‐shock protein‐27 inhibit the growth of non‐muscle‐invasive bladder cancer
JP2007523893A5 (https=)
Lapucci et al. Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice
JP2009541387A5 (https=)
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
Katada et al. Significance of vascular endothelial cell growth factor up-regulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas
ATE526023T1 (de) Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
CN111656195A (zh) 单核/巨噬细胞在主动脉损伤中的诊断和治疗应用